Actively Recruiting
Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe
Led by Peking University Cancer Hospital & Institute · Updated on 2024-08-19
20
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the clinical predictive value of 68Ga-DOTA-BPP in subjects with triple-negative breast cancer. The visual and semiquantitative methods will be used to assess the PET/CT images
CONDITIONS
Official Title
Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- ECOG performance status of 0 or 1
- Confirmed triple-negative breast cancer with a clinical recommendation for PET/CT imaging for tumor diagnosis or staging
You will not qualify if you...
- Pregnant or nursing
- Severe liver or kidney dysfunction
- Low white blood cell count (less than 3 x 10^9/L)
- Unable to comply with PET/CT imaging procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ethics Committee of Peking University Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Research Team
Q
Qian Zhang
CONTACT
H
Hua Zhu, M.D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here